| Previous close | 12.90 |
| Open | 12.90 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 12.90 - 12.90 |
| 52-week range | 12.80 - 14.10 |
| Volume | |
| Avg. volume | 350 |
| Market cap | 170.372M |
| Beta (5Y monthly) | 0.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.39 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 21.00 |
Business WireAelis Farma Reports Its 2023 Annual Financial Resultsand Confirms Its 2024 Outlook
BORDEAUX, France, April 02, 2024--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, today announces its full year results for the year to December 31, 2023.
- Business Wire
Aelis Farma Announces Its 2024 Financial Calendar
BORDEAUX, France, January 30, 2024--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases, today announces its indicative financial calendar for the financial year 2024.
- Business Wire
Aelis Farma Strengthens its Leadership Team with the Appointment of Arsène Guekam as Chief Corporate Development Officer
BORDEAUX, France, January 17, 2024--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS) (Paris: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain disorders, today announces the reinforcement of its leadership team with the appointment of Arsène Guekam as Chief Corporate Development Officer (CDO).
